Best Phosphate Binders in CKD
For adults with CKD requiring phosphate control, non-calcium-based phosphate binders (particularly sevelamer, lanthanum, or iron-based binders) are preferred over calcium-based binders, with the dose of calcium-based binders restricted when used. 1
Key Guideline Recommendations
The 2017 KDIGO guidelines provide clear direction on phosphate binder selection:
Restrict the dose of calcium-based phosphate binders in adults with CKD G3a-G5D receiving phosphate-lowering treatment (Grade 2B recommendation) 2
Choice should be individualized based on CKD stage, presence of other CKD-MBD components, concomitant therapies, and side effect profile 2
Further restrict calcium-based binders in the presence of:
- Arterial calcification (2C)
- Adynamic bone disease (2C)
- Persistently low serum PTH levels (2C) 2
Evidence Supporting Non-Calcium-Based Binders
Mortality Benefit
The most compelling evidence comes from studies comparing sevelamer to calcium-based binders in dialysis patients:
- Sevelamer may reduce all-cause mortality by approximately 50% compared to calcium-based binders in CKD G5D (RR 0.53,95% CI 0.30-0.91) 3
- In absolute terms: mortality risk decreases from 210 per 1000 to 105 per 1000 over up to 36 months 3
- A network meta-analysis confirmed higher mortality with calcium versus sevelamer (RR 1.89,95% CI 1.02-3.50, moderate quality evidence) 4
Reduced Hypercalcemia Risk
Non-calcium-based binders substantially reduce hypercalcemia risk:
- Sevelamer reduces hypercalcemia compared to calcium (RR 0.30,95% CI 0.20-0.43) 3
- Lanthanum reduces hypercalcemia compared to calcium (RR 0.16,95% CI 0.06-0.43) 3
Vascular Calcification Concerns
The evidence reveals a critical safety signal for calcium-based binders:
In patients with CKD G3b-G4 with normal phosphate levels, calcium-based binders (particularly calcium acetate) caused progression of coronary and aortic calcification, while placebo did not 1. This finding fundamentally changed the approach to phosphate binder use in earlier CKD stages.
Specific Binder Options
First-Line Non-Calcium Options:
Sevelamer (hydrochloride or carbonate)
- Strongest mortality data in dialysis patients
- May cause constipation (RR 6.92 vs placebo) 3
Lanthanum carbonate
Iron-based binders (ferric citrate, sucroferric oxyhydroxide)
When Calcium-Based Binders Are Used:
If calcium-based binders are prescribed, keep doses as low as possible 1. The evidence shows that positive calcium balance can cause harm, particularly vascular calcification 1.
Critical Clinical Caveats
Do NOT Use Phosphate Binders:
- In normophosphatemic patients with CKD G3a-G5 for prevention 1
- Treatment should only be initiated for progressively or persistently elevated serum phosphate 2
Important Pitfall to Avoid:
The older practice of liberally using calcium-based binders is now contraindicated based on vascular calcification data. Not all phosphate binders are interchangeable - calcium acetate in particular showed harm in the pivotal trial 1.
Contradictory Evidence Note:
One recent observational study in patients ≥65 years found no cardiovascular benefit of sevelamer over calcium acetate (HR 0.96,95% CI 0.84-1.10) 5. However, this conflicts with the higher-quality randomized trial data and meta-analyses showing mortality benefit. The guideline recommendations appropriately prioritize the randomized evidence.
Practical Algorithm
For CKD G3a-G5 (non-dialysis):
- Start phosphate binders ONLY if phosphate is progressively/persistently elevated
- Prefer non-calcium-based binders (sevelamer, lanthanum, or iron-based)
- If using calcium-based: minimize dose and monitor for vascular calcification
For CKD G5D (dialysis):
- Prefer non-calcium-based binders given mortality data
- Sevelamer has the strongest evidence base
- Restrict calcium-based binder doses if used
- Absolutely avoid calcium-based binders if: arterial calcification present, adynamic bone disease, or persistently low PTH